Skip to main content
Fig. 5 | BMC Medicine

Fig. 5

From: Towards the concept of disease-modifier in post-stroke or vascular cognitive impairment: a consensus report

Fig. 5

Early phases of strategy development through a matrix approach using a biomarker battery. The aim of this process is to reinforce the rationale of Go/No Go decision before the translation to phase 3. For each animal or clinical study, the effect level should be determined and integrated into a matrix model in order to properly assess the relevance of the tested strategy

Back to article page
\